Your browser doesn't support javascript.
loading
Lung adenocarcinoma promotion by air pollutants.
Hill, William; Lim, Emilia L; Weeden, Clare E; Lee, Claudia; Augustine, Marcellus; Chen, Kezhong; Kuan, Feng-Che; Marongiu, Fabio; Evans, Edward J; Moore, David A; Rodrigues, Felipe S; Pich, Oriol; Bakker, Bjorn; Cha, Hongui; Myers, Renelle; van Maldegem, Febe; Boumelha, Jesse; Veeriah, Selvaraju; Rowan, Andrew; Naceur-Lombardelli, Cristina; Karasaki, Takahiro; Sivakumar, Monica; De, Swapnanil; Caswell, Deborah R; Nagano, Ai; Black, James R M; Martínez-Ruiz, Carlos; Ryu, Min Hyung; Huff, Ryan D; Li, Shijia; Favé, Marie-Julie; Magness, Alastair; Suárez-Bonnet, Alejandro; Priestnall, Simon L; Lüchtenborg, Margreet; Lavelle, Katrina; Pethick, Joanna; Hardy, Steven; McRonald, Fiona E; Lin, Meng-Hung; Troccoli, Clara I; Ghosh, Moumita; Miller, York E; Merrick, Daniel T; Keith, Robert L; Al Bakir, Maise; Bailey, Chris; Hill, Mark S; Saal, Lao H; Chen, Yilun.
Afiliación
  • Hill W; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Lim EL; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Weeden CE; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Lee C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Augustine M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Chen K; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Kuan FC; Division of Medicine, University College London, London, UK.
  • Marongiu F; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Evans EJ; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Moore DA; Division of Medicine, University College London, London, UK.
  • Rodrigues FS; Tumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute, London, UK.
  • Pich O; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Bakker B; Department of Thoracic Surgery and Thoracic Oncology Institute, Peking University People's Hospital, Beijing, China.
  • Cha H; Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi, Taiwan.
  • Myers R; Graduate Institute of Clinical Medical Sciences, Chang-Gung University, Taoyuan, Taiwan.
  • van Maldegem F; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Boumelha J; Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
  • Veeriah S; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Naceur-Lombardelli C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Karasaki T; Department of Cellular Pathology, University College London Hospitals, London, UK.
  • Sivakumar M; Tumour-Host Interaction Laboratory, The Francis Crick Institute, London, UK.
  • De S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Caswell DR; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Nagano A; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Black JRM; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Martínez-Ruiz C; BC Cancer Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
  • Ryu MH; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.
  • Huff RD; Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Li S; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.
  • Favé MJ; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Magness A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Suárez-Bonnet A; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Priestnall SL; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Lüchtenborg M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Lavelle K; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.
  • Pethick J; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Hardy S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • McRonald FE; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Lin MH; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Troccoli CI; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Ghosh M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Miller YE; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Merrick DT; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Keith RL; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Al Bakir M; Department of Medicine, Division of Respiratory Medicine, Chan-Yeung Centre for Occupational and Environmental Respiratory Disease, Vancouver Coastal Health Research Institute, UBC, Vancouver, British Columbia, Canada.
  • Bailey C; Department of Medicine, Division of Respiratory Medicine, Chan-Yeung Centre for Occupational and Environmental Respiratory Disease, Vancouver Coastal Health Research Institute, UBC, Vancouver, British Columbia, Canada.
  • Hill MS; Department of Medicine, Division of Respiratory Medicine, Chan-Yeung Centre for Occupational and Environmental Respiratory Disease, Vancouver Coastal Health Research Institute, UBC, Vancouver, British Columbia, Canada.
  • Saal LH; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chen Y; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Nature ; 616(7955): 159-167, 2023 04.
Article en En | MEDLINE | ID: mdl-37020004
ABSTRACT
A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process an initiating step that induces mutations in healthy cells, followed by a promoter step that triggers cancer development1. Here we propose that environmental particulate matter measuring ≤2.5 µm (PM2.5), known to be associated with lung cancer risk, promotes lung cancer by acting on cells that harbour pre-existing oncogenic mutations in healthy lung tissue. Focusing on EGFR-driven lung cancer, which is more common in never-smokers or light smokers, we found a significant association between PM2.5 levels and the incidence of lung cancer for 32,957 EGFR-driven lung cancer cases in four within-country cohorts. Functional mouse models revealed that air pollutants cause an influx of macrophages into the lung and release of interleukin-1ß. This process results in a progenitor-like cell state within EGFR mutant lung alveolar type II epithelial cells that fuels tumorigenesis. Ultradeep mutational profiling of histologically normal lung tissue from 295 individuals across 3 clinical cohorts revealed oncogenic EGFR and KRAS driver mutations in 18% and 53% of healthy tissue samples, respectively. These findings collectively support a tumour-promoting role for  PM2.5 air pollutants  and provide impetus for public health policy initiatives to address air pollution to reduce disease burden.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Transformación Celular Neoplásica / Contaminantes Atmosféricos / Contaminación del Aire / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Nature Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Transformación Celular Neoplásica / Contaminantes Atmosféricos / Contaminación del Aire / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Nature Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido